Intervention in acute myocardial infarction page 1
Intervention in acute myocardial infarction page 2
Intervention in acute myocardial infarction page 3
Intervention in acute myocardial infarction page 4

Intervention in acute myocardial infarction

  • View

  • Download

Embed Size (px)

Text of Intervention in acute myocardial infarction



    Oral Abstract Presentations12:002:15 PM

    Intervention in Acute MyocardialInfarction

    Monday, September 15, 2003

    12:00-2:15 PMRoom 201

    (Abstract nos. 1-9)

    TCT-1A Randomized Trial of a Rapamycin-Eluting Stent in AcuteMyocardial Infarction: Preliminary Results. V. Pasceri,A. Granatelli, C. Pristipino, F. Pelliccia, G. Speciale, B. Pironi,A. Roncella, G. Richichi. Emodinamica, San Filippo Neri Hospital,Rome, Italy

    Background: Several clinical trials have shown that rapamycin-elutingstents are highly effective in reducing restenosis following percutane-ous transluminal coronary angioplasty. No study to date, however, hasassessed the safety and effectiveness of drug-eluting stents in acutemyocardial infarction (AMI). Indeed, AMI has been an exclusioncriteria in previous trials because of the risk of stent thrombosis.

    Methods: We performed a randomized, controlled trial comparingthe CYPHER rapamycin-eluting stent with the BX Sonic stent in AMI.Inclusion criteria were ST-elevation AMI within 24 hours of symptomonset and 2.5- to 3.0-mm vessel size. We excluded patients withcardiogenic shock and with obvious contraindications to ticlopidinetreatment. Preliminary results of the first 34 patients (aged 62 9years, 74% men, 23% with diabetes) are presented.

    Results: Of our sample, 18 patients received an average of 1.5 0.7 CYPHER stents (diameter 2.9 0.2, total length 30 13 mm), and15 patients received an average of 1.4 0.7 BX stents (diameter 2.90.2, total length 28 10 mm). Abciximab was used in 97% of cases.Angiographic follow-up at 6 months is ongoing (it has been performedin 40% of cases and will be available at the time of presentation). Therewere no in-hospital events. All patients with the CYPHER stent re-ceived ticlopidine for 6 months (1 month only for BX stent). Afterdischarge, however, 3 patients in the CYPHER group and 1 in the BXgroup stopped ticlopidine due to noncompliance or contraindications.At 4 2 months follow-up, there were 2 subacute thrombosis in theCYPHER group (at 710 days after discharge); both patients had

    stopped ticlopidine treatment. No subacute thrombosis occurred in theBX group. There were no cases of clinical restenosis or other events inthe 16 CYPHER patients who continued ticlopidine treatment. Overall,there were 10% new target vessel revascularizations in the CYPHERgroup and 13% in the BX group, but 0% and 14%, respectively, amongpatients taking ticlopidine.

    Conclusion: Use of CYPHER stent in AMI appears to be a pos-sibility, but there is a high risk of stent thrombosis in patients who donot take ticlopidine. Further studies using drug-eluting stents shouldtake into account the problem of noncompliance to ticlopidine andclopidogrel treatment, which can increase the risk of thrombosis.

    TCT-2Facilitated Percutaneous Coronary Intervention ReducesMortality in Patients With Cardiogenic Shock Due to AcuteMyocardial Infarction. S. Rux, K. Lenen, S. Sonntag, L. Bruch,P.E. Waurick, F.X. Kleber. Department of Internal Medicine,Division of Cardiology, UKB, Academic Teaching Hospital FreeUniversity, Berlin, Germany.

    Background: Acute myocardial infarction (AMI) mortality in patients(pts) suffering from cardiogenic shock (CS) is high (5060%). Recentstudies suggest that the addition of GPIIb/IIIa inhibitors to eitherthrombolysis (reduced dosage) or primary percutaneous coronary in-tervention (PCI) offers advantages in myocardial salvage and possiblyimproved prognosis.

    Methods: We investigated the effects of facilitation of PCI in ptspresenting with cardiogenic shock. Pts were pretreated with GPIIb/IIIainhibitors before cardiac cath and, if cardiac cath was delayed beyond60 minutes, also with a reduced dose of rPA (rtPA). CS was defined asa systolic blood pressure 90 mm Hg for at least 30 minutes withsevere organ hypoperfusion or the need to use catecholamines tostabilize hemodynamics.

    Results: Among 600 AMI pts treated at our institution betweenJanuary 1999 and March 2003, 76 (12.7%) required cardiopulmonaryresuscitation (before hospital arrival or in hospital), 86 (14.3%) pre-sented with CS, and 21 of the remaining pts (4.1%) developed cardio-genic shock during hospitalization. Of the total 600 pts, 199 werepretreated with GP inhibitors and reduced-dosage thrombolytics forfacilitation before cardiac cath. Of these pts, 16.1% presented with CS,and 1.2% of the initially hemodynamically stable pts developed CS.Among 401 pts treated with GP inhibitors alone for facilitation, 54(13.5%) presented with CS, and 5.5% of the remaining pts developedCS. Therefore, significantly fewer pts developed CS after additionalpretreatment with a half dose of thrombolytics (p 0.03). Overallhospital mortality was 3.3% and 15.9% in pts suffering from CS.Overall mortality after 180 days was 6.4% in 471 pts who havecurrently reached this follow-up and 20.7% in pts suffering from CS.

    Conclusion: We conclude that facilitated PCI in AMI with cardio-genic shock reduces hospital and long-term mortality. The addition ofreduced doses of thrombolytics can prevent the development of CS.

    TCT-3Feasibility of Endovascular Cooling as an Adjunct to PrimaryPercutaneous Coronary Intervention: Results of the LOWTEMPPilot Study. E. Kandzari1, A. Chu2, B.R. Brodie3, T.A. Stuckey3,J. Hermiller4, G. Vetrovec5, K.L. Hannan1, M.W. Krucoff1,R.H. Christenson6, R. Gibbons7, K.N. Sigmon1, K. Collins8,R.A. Harrington1, R.M. Califf1. 1Duke Clinical Research Institute,Durham, North Carolina, USA; 2HeartCare Midwest, Peoria,Illinois, USA; 3Moses Cone Heart and Vascular Center, Greensboro,North Carolina, USA; 4St Vincent Hospital, Indianapolis, Indiana,USA; 5Medical College of Virginia, Richmond, Virginia, USA;6University of Maryland School of Medicine, Baltimore, Maryland,

    The American Journal of Cardiology SEPTEMBER 1517, 2003 TCT ABSTRACTS/Oral 1L



    MONDAY 09/15/03 12:002:15 PM (Room 201)

  • USA; 7Mayo Clinic, Rochester, Minnesota, USA; 8AlsiusCorporation, Irvine, California, USA

    Background: Restoring myocardial perfusion and metabolism is fun-damental to limiting infarct size and enhancing survival. Early expe-rience with therapeutic hypothermia during acute myocardial infarction(AMI) has demonstrated cardioprotective effects.

    Methods: Twenty AMI patients with high-risk characteristics wererecruited to undergo adjunctive endovascular cooling (Alsius, Irvine,California) immediately prior to primary percutaneous coronary inter-vention (PCI) to achieve a target core body temperature of 32 to 34C.In addition to safety and tolerability, the primary endpoint was definedas a composite of infarct size (area under the curve [AUC] CK-MB andTc-99m SPECT sestamibi) and quality of myocardial perfusion (24-hour continuous ST-segment monitoring).

    Results: Eighteen patients underwent catheter-based hypothermiato achieve a mean core body temperature of 33.7 0.9 C (mean SD) for a total cooling period of 4.5 1.8 hours. By 7 days, 1 (5.6%)patient developed ventricular fibrillation, and 3 (16.7%) patients expe-rienced bradycardia requiring intervention. Median infarct size (25th,75th percentiles was 4.0% (0, 19.0) by 30-day SPECT sestamibi and3232.8 (1671.4, 6729.1) hours ng/mL by AUC CK-MB. The medianextent of ST-segment recovery was 78.8% (68.1, 95.8), and recurrentischemia occurred in 2 (11.1%) patients per electrocardiographic mon-itoring. At 30 days, 1 death occurred, and 4 patients underwent urgentrepeat revascularization. There were no episodes of stroke, reinfarction,or major bleeding.

    Conclusion: In this nonrandomized feasibility study, endovascularcooling in high-risk AMI patients successfully reduced core bodytemperature as an adjunct to primary PCI. These results support theevaluation of adjunctive hypothermia in pivotal trials to limit infarctsize and reduce reperfusion injury.

    TCT-4Late Primary Angioplasty: Is Early Left Ventricular FunctionRecovery Achievable? J.L. Szarfer, A. Garcia Escudero,S. Massone, S. Affatatto, R. Sarmiento. M.A. Riccitelli HospitalArgerich, Buenos Aires, Argentina.

    Background: Improvement of left ventricular function (LVF) afterperforming a primary angioplasty is a major achievement. The TAMI-6trial has demonstrated that coronary reperfusion 6 hours after onset(ie, late) in patients with acute myocardial infarction (AMI) does notimprove LVF during the chronic phase of infarction. However, the lowpatency rate (only 60%) of the infarct-related artery during the chronicphase in the TAMI-6 trial raises a new hypothesis that late reperfusionwith a higher patency rate may improve LVF. The aim of this study wasto evaluate the achievement of early recovery in LVF after a successfullate primary percutaneous coronary intervention (PCI), performed 6hours after symptom onset.

    Methods: End diastolic volume in mL/m2 (EDV), end systolicvolume in mL/m2 (ESV), ejection fraction (EF), and regional wallmotion were evaluated in 2 ventriculograms performed immediatelybefore and 24 hours after PCI in 100 consecutive patients (pts) withAMI, undergoing the procedure between 6 and 12 hours followingsymptom onset. TIMI 3 flow grade was achieved in all patients,remaining unchanged at the 24-hour angiography. Ventricular volumesand EF were assessed through the area-length method; regional wallmotion was evaluated through the centerline chord method. Patients(pts) were aged 59 11.3 years; 81 pts were men; 28 pts had aprevious myocardial infarction history, 52 pts had 1-vessel disease, 32pts had 2-vessel disease, and 16 pts had 3-vessel. The procedure wasperformed on the anterior descending artery in 51 pts, the circumflexartery in 14 pts, and the right coronary artery in 35 pts. Statistical

    analysis included 2-tailed Student t test, analysis of variance, andchi-square test.

    Results: EDV remained unc